menu search

xilio therapeutics announces pipeline and business updates and first quarter 2023 financial results

Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity d...

May 9, 2023, 11:30 am

xilio therapeutics to present at upcoming investor conferences

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnolo...

February 27, 2023, 7:30 am

xilio therapeutics to present at the guggenheim healthcare talks oncology day

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) — xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnol...

February 2, 2023, 12:30 pm

xilio therapeutics to host live virtual program spotlighting xtx301, a tumor-activated il-12

WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) — xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnol...

November 23, 2022, 12:30 pm

Nuformix hails progress partner is making with reformulated anti-sickness drug

Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development...

February 8, 2022, 2:57 am

Nuformix hails progress partner is making with reformulated anti-sickness drug

Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development...

February 8, 2022, 2:57 am

Nuformix hails progress partner is making with reformulated anti-sickness drug

Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development...

February 8, 2022, 2:57 am


Search within

Pages Search Results: